-
One year after the end of the pilot, the traditional Chinese medicine formula granule industry is moving towards high standards
Time of Update: 2022-11-26
Under the high threshold and high standard, in the past year, the market pattern of the traditional Chinese medicine formula granule industry has been adjusted steadily: those who have entered the game have made efforts to improve core competitiveness such as product quality, and those who intend to enter the game carefully observe and do what they can.
-
National Health Commission: Classify and treat new crown pneumonia patients to truly achieve "four mornings"
Time of Update: 2022-11-25
At the press conference, Guo Yanhong, director of the Department of Medical Emergency Response of the National Health Commission, said that the capacity building of medical services and the preparation of treatment resources will be strengthened, and the new crown pneumonia patients will be treated by level and classification.
-
Stone medicine broke out! Won 17 heavy varieties and 85 evaluated varieties are eye-catching
Time of Update: 2022-11-25
com China Clinical Trial Library Improved new drugs have attacked high-end preparations such as liposomes, micelles, and albumin-binding types, and many of the generic drugs involved in these products exceeded 1 billion yuan in 2021 in China's public medical institutions, including alprostadil (1 billion+), docetaxel (3 billion+), irinotecan (1.
-
When benefit-risk assessment becomes the focus, a new round of supply-side reform of innovative drugs begins
Time of Update: 2022-11-25
According to the Draft Opinion, the marketing application of innovative drugs: the benefits of drugs – risk assessment is a key process in regulatory decision-making, which ultimately determines whether it is approved.
-
43 companies were surveyed by institutions, and pharmaceutical and other industries were favored
Time of Update: 2022-11-25
js?cdnversion='+~(-new Date()/36e5)];According to the statistics of the Oriental Wealth Network institutional survey, on November 16, a total of 43 companies were surveyed by institutions, and the industries intensively investigated by institutions mainly involved communications, electronics, medicine and other industries.
-
$2 billion! The multinational pharmaceutical company launched a new acquisition
Time of Update: 2022-11-25
On November 15, Roche announced the $2 billion acquisition of Jnana's RAPID platform, which will leverage its RAPID chemical proteomics platform to discover novel small molecule drugs for cancer, tumor, immune-mediated and neurological diseases.
-
In cold weather, the "four types of drugs" are hot, and chain pharmacies are expected to continue to improve in the fourth quarter
Time of Update: 2022-11-25
The three chain heads of Da Shenlin, Laomin and Yifeng Pharmacy increased their revenue and profits in the first three quarters, achieving revenue of 14.
The three chain heads of Da Shenlin, Laomin and Yifeng Pharmacy increased their revenue and profits in the first three quarters, achieving revenue of 14.
-
The API industry has attracted much attention recently, and corporate dynamics are continuous
Time of Update: 2022-11-25
Hanyu Pharmaceutical recently announced that the company's desmopressin acetate API received the CEP (European Pharmacopoeia Applicability Certification) certificate issued by the European Medicines Quality Agency.
Hanyu Pharmaceutical recently announced that the company's desmopressin acetate API received the CEP (European Pharmacopoeia Applicability Certification) certificate issued by the European Medicines Quality Agency.
-
Multinational pharmaceutical companies are accelerating the "subtraction" of non-core assets, focusing on oncology and other fields
Time of Update: 2022-11-25
In addition, multinational pharmaceutical companies such as Johnson & Johnson are also divesting or spinning off consumer or generic drug businesses recently, focusing more energy and financial resources on core areas.
-
The traditional Chinese medicine market may usher in a new round of reshuffle, and promoting the standardized development of the industry will become a new focus for pharmaceutical companies
Time of Update: 2022-11-25
The traditional Chinese medicine market may usher in a reshuffle, and standardized development will become the focus of pharmaceutical companies (Image source: Pharmaceutical Network) Among them, it is worth mentioning that a provision stipulates that if any of the [contraindications], [adverse reactions] and [precautions] of Chinese medicines is still "unclear" when applying for drug re-registration, it will not be re-registered.
-
4 manufacturers and 3 countries talk about generic drugs to determine the price limit of centralized procurement
Time of Update: 2022-11-25
On November 15, Anhui Pharmaceutical Centralized Procurement Center issued an announcement to adjust the centralized procurement properties and prices of three drugs. These three drugs are dapagliflo
-
Deputy general managers of 2 pharmaceutical companies, resigned due to personal reasons
Time of Update: 2022-11-25
js?cdnversion='+~(-new Date()/36e5)];On November 16, YaoTesco issued an announcement that Hao Ruizhi recently applied to resign as the secretary of the company's board of directors and deputy general manager due to personal reasons.
-
The market continues to expand, and pharmaceutical companies are accelerating their entry into the CRO field
Time of Update: 2022-11-25
It is understood that in recent years, in the context of the continuous deepening of domestic medical reform, the consistency evaluation of generic drugs has opened the market access and reshuffle of existing pharmaceutical products, and the priority review and approval, drug marketing authorization holder system greatly encourages the innovation and upgrading of the entire industry and the professional division of labor, the CRO industry is ushering in huge development opportunities.
-
Two local pharmaceutical companies join forces to expand overseas markets!
Time of Update: 2022-11-25
In addition, the drug has also been granted orphan drug designation by the US Food and Drug Administration (FDA) for the indication of extensive-stage small cell lung cancer, and Henlius plans to submit a marketing application for this indication in the United States in the first half of 2024.
-
813 medical institutions in Beijing, Tianjin, Hebei and Lu provinces and cities have achieved mutual recognition of test results
Time of Update: 2022-11-25
In order to facilitate the people's medical treatment and avoid repeated examinations, Beijing, Tianjin, Hebei and Shandong provinces and cities jointly carried out mutual recognition of clinical test results of regional medical institutions.
-
The development of the domestic medical device industry continues to improve, and the competition between domestic and foreign enterprises will intensify
Time of Update: 2022-11-25
News on November 16, medical device company Tandem Diabetes Care announced that the company's global sales in the third quarter of 2022 increased by 14% to $204.
-
CanSino Biologics inhaled new crown vaccine in Beijing fully started vaccination
Time of Update: 2022-11-25
According to the public account of CanSino Biologics, recently, Beijing has fully carried out the appointment and vaccination of CanSino Biologics recombinant new coronavirus vaccine (adenovirus type
-
A large number of multinational pharmaceutical companies are gearing up to bring more innovative products to the Chinese market!
Time of Update: 2022-11-15
With the introduction of the "Healthy China 2030" planning outline and the continuous improvement of the policy environment, China's pharmaceutical innovation industry continues to release vitality,
-
"Good physique, raise up", more Chinese medicine scriptures to maintain health, just in Zhongjing Health Festival!
Time of Update: 2022-11-15
Zhongjing Health Festival, invigorate qi and strengthen the spleen without insomniaMany people often fall into a vicious circle when facing insomnia, insomnia brings emotional anxiety and irritability, but further aggravates insomnia, and is also prone to hair loss, memory loss and other problems.
-
In the fourth quarter, the performance of the pharmaceutical sector is worth looking forward to!
Time of Update: 2022-11-15
89% so far this year, but from the current point of view, the industry generally believes that the valuation of the pharmaceutical sector has basically been adjusted in place, the pharmaceutical company's 2022 third quarter report overall exceeded expectations, pharmaceutical stocks gradually rose, coupled with the resonance of factors such as the recovery of innovative drug policies, it is expected that the performance of the next pharmaceutical sector is worth looking forward to.
